The Deal
Tuesday, November 24, 
9:05 pm

Icahn's BEA, Biogen juggle

  Share     E-Mail    Discussion    Print Story

Activist investor Carl Icahn is a busy man, who is not only attempting to push software company BEA Systems Inc. to sell, but also is pushing for a sale at Cambridge, Mass., biotechnology company Biogen Idec Inc.

Continue reading below

Also on Dealscape

Monday's Wall Street Journal features an update on Icahn's activities at Biogen Idec. Despite skepticism amongst Wall Street analysts about Biogen Idec's pipeline, Icahn is upbeat about its future drugs saying it is an ideal takeover candidate for a Big Pharma.

Meanwhile, Icahn is threatening to sue BEA, which responded Monday morning by sending its biggest shareholder a letter saying it is still looking at ways to maximize shareholder value, including a possible sale. The software company allowed a $17 a share offer from Oracle Corp. to expire on Sunday. — Matthew Wurtzel

See BEA Systems story from TheDeal.com
See Biogen Idec story from Wall Street Journal (subscription may be required)
See Icahn Dealwatch





Post a comment





The Deal Pipeline

Deal Video


Inside The Deal: Cisco Systems' Ned Hooper on raising the bid for Tandberg.


More video...

Crisis On Wall Street
Technology
Deals of The Decade

Community

Industry Insight

REIT IPO deja vu

Real estate sponsors that might wish to undertake an IPO will need to consider a wide variety of issues and begin to take action long before the first filing with the SEC.


Industry Insight

Loan-to-buy

Paulson's proposal to purchase an equity stake in Yellow Pages publisher Idearc is the second time in recent months an investor group has used its prepetition debt position to execute a bargain price 'exit LBO.'


Industry Insight

Managing your shareholder base

Growth companies and their PE sponsors should be wary of the pitfalls that arise when they layer on tiers of preferred stock.


footspacer.jpg footspacer.jpg footspacer.jpg footspacer.jpg footspacer.jpg


©Copyright 2009, The Deal, LLC. All rights reserved. Please send all technical questions, comments or concerns to the Webmaster.